Robert Mbilinyi, MS. and Vytas Bankaitis, Ph.D.

Introduction: Gliomas, a diverse group of tumors originating from glial cells in the central nervous system (CNS), are the most common type of CNS tumors^1,2. They include astrocytomas, oligodendrogliomas, and glioblastomas, with glioblastomas being the most dangerous, accounting for over 70-75% of CNS tumor deaths². Standard treatment options such as surgery, radiation, and chemotherapy have limitations, leading to a high rate of recurrence^1,3,4. Consequently, immunotherapy has emerged as a promising approach for treatment-resistant gliomas, targeting the disialoganglioside glycolipid GD2 expressed by glioma cells through genetically engineered T cells with chimeric antigen receptors (CARs) specific for GD2⁵.

Methods: In this analysis, we scrutinized the latest progress in GD2 CAR T cell therapy for combating treatment-resistant gliomas. A systematic literature search of the PubMed database (2018-2023) employed the following key terms: “gliomas”, “treatment-resistant gliomas”, “GD2-CAR-T therapy”, and “neuroimmunology”.

Results: To address treatment limitations of these treatment-resistant gliomas, immunotherapy targeting GD2 on glioma cells has been developed⁵. GD2-CAR T cells have been studied in vitro and in vivo, demonstrating significant antitumor effects against GD2-positive glioma cells ^6,7. Phase one clinical trials tested the feasibility, safety, and clinical benefits of GD2-CAR T cell therapy in patients with H3K27M-mutated diffuse midline gliomas ^5,8. GD2-CAR T cell therapy showed effective trafficking to glioma sites, eliminating the immunologically cold tumor environment and providing evidence of antitumor activity⁵. In some cases, treatment led to partial or complete tumor responses, with significant reductions in tumor size and improved overall survival⁵. The therapy was well-tolerated, with minimal side effects reported in preclinical models and clinical trials, supporting its potential as a safe and effective immunotherapy for gliomas ^5,8,9.

Conclusion: Despite promising results, further research is needed to optimize GD2-CAR T cell therapy and understand mechanisms of resistance. Future studies should focus on enhancing the persistence and expansion of GD2-CAR T cells, identifying biomarkers to predict treatment response, and developing preclinical models that more accurately recapitulate human disease for improved translational potential. Combination therapy targeting multiple pathways involved in tumor growth and immune evasion may also improve treatment outcomes. Another area of focus is the optimization of CAR T cell design to increase specificity and further reduce off-target effects. Additionally, improving delivery methods for CAR T cells may enhance their efficacy in targeting gliomas. Finally, personalized treatment approaches may be necessary to account for the heterogeneity of gliomas and the unique characteristics of individual patients. By addressing these challenges, GD2-CAR T cell therapy holds significant promise for the treatment of gliomas and warrants continued investigation to realize its full therapeutic potential.

Works Cited:

1. Davis ME. Epidemiology and Overview of Gliomas. Semin Oncol Nurs. 2018;34(5):420-429. doi:10.1016/J.SONCN.2018.10.001
2. Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019;15(7):405. doi:10.1038/S41582-019-0220-2
3. Henderson F, Abdullah KG, Verma R, Brem S. Tractography and the connectome in neurosurgical treatment of gliomas: the premise, the progress, and the potential. Neurosurg Focus. 2020;48(2):E6. doi:10.3171/2019.11.FOCUS19785
4. Sledzí Nska P, Bebyn MG, Furtak J, et al. Molecular Sciences Prognostic and Predictive Biomarkers in Gliomas. J Mol Sci. 2021;22:10373. doi:10.3390/ijms221910373
5. Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934. doi:10.1038/S41586-022-04489-4
6. Moghimi B, Muthugounder S, Jambon S, et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun. 2021;12(1). doi:10.1038/S41467-020-20785-X
7. Prapa M, Chiavelli C, Golinelli G, et al. GD2 CAR T cells against human glioblastoma. NPJ Precis Oncol. 2021;5(1). doi:10.1038/S41698-021-00233-9
8. Mount CW, Majzner RG, Sundaresh S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med. 2018;24(5):572-579. doi:10.1038/S41591-018-0006-X
9. De Billy E, Pellegrino M, Orlando D, et al. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. Neuro Oncol. 2022;24(7):1150-1163. doi:10.1093/NEUONC/NOAB300